Global Biosimilar Drug Market Insights, Forecast to 2025
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
As healthcare costs continue to rise, biosimilars offer new therapeutic options with the potential for cost savings to the healthcare system. With anticipated savings, biosimilars bring hope that there will be expanded access for patients to not only these known therapies, but also to new innovative medicines. At Amgen, serving patients is at the core of what we do and it is why we’re using our more than 35 years of biologics experience to develop high-quality biosimilars.
First, in pharmerging markets, both governments and patients struggle to pay for biosimilars, which encouraged the demand of biosimilars, therefore in the future the biosimilars will grow around 20%.
Second, generally, biosimilars industry is still in their infancy in China. It is commonly believed that the next 10 to 15 years is the golden period of the development of biosimilars.
Third, for the biosimilars industry, technical barriers will be much smaller, in the next few years, there will be more and more enterprises going into biosimilars industry.
Forth, most of biosimilars manufacturer are concentrated in US, Germany, UK and other developed countries.
At last, through the research we tend to believe that the biosimilars, now is a chance for newcomers and they will greatly change the industry.
The global Biosimilar Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Biosimilar Drug market based on company, product type, end user and key regions.
This report studies the global market size of Biosimilar Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biosimilar Drug in these regions.
This research report categorizes the global Biosimilar Drug market by top players/brands, region, type and end user. This report also studies the global Biosimilar Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen
Eli Lilly
Novartis
CP Guojian Pharma
Biotech Pharma
Market size by Product
Injection
Tablets
Other Types
Market size by End User
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Biosimilar Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Biosimilar Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Biosimilar Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Biosimilar Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Biosimilar Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K DDD). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Biosimilar Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
As healthcare costs continue to rise, biosimilars offer new therapeutic options with the potential for cost savings to the healthcare system. With anticipated savings, biosimilars bring hope that there will be expanded access for patients to not only these known therapies, but also to new innovative medicines. At Amgen, serving patients is at the core of what we do and it is why we’re using our more than 35 years of biologics experience to develop high-quality biosimilars.
First, in pharmerging markets, both governments and patients struggle to pay for biosimilars, which encouraged the demand of biosimilars, therefore in the future the biosimilars will grow around 20%.
Second, generally, biosimilars industry is still in their infancy in China. It is commonly believed that the next 10 to 15 years is the golden period of the development of biosimilars.
Third, for the biosimilars industry, technical barriers will be much smaller, in the next few years, there will be more and more enterprises going into biosimilars industry.
Forth, most of biosimilars manufacturer are concentrated in US, Germany, UK and other developed countries.
At last, through the research we tend to believe that the biosimilars, now is a chance for newcomers and they will greatly change the industry.
The global Biosimilar Drug market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Biosimilar Drug market based on company, product type, end user and key regions.
This report studies the global market size of Biosimilar Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Biosimilar Drug in these regions.
This research report categorizes the global Biosimilar Drug market by top players/brands, region, type and end user. This report also studies the global Biosimilar Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Amgen
Eli Lilly
Novartis
CP Guojian Pharma
Biotech Pharma
Market size by Product
Injection
Tablets
Other Types
Market size by End User
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Biosimilar Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Biosimilar Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Biosimilar Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Biosimilar Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Biosimilar Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K DDD). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Biosimilar Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
